These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 18936884)

  • 1. Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer.
    Saeki T; Okita A; Aogi K; Kakishita T; Okita R; Taira N; Ohama Y; Takashima S; Nishikawa K
    Breast Cancer; 2009; 16(2):113-20. PubMed ID: 18936884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer].
    Sakurai K; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2246-8. PubMed ID: 21224536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The combined effect of paclitaxel and toremifene therapy for metastatic breast cancer].
    Sakurai K; Matsuo S; Enomoto K; Amano S; Shiono M
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):1994-6. PubMed ID: 20037302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
    Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for relapsed breast cancer.
    Kim R; Osaki A; Toge T
    Oncol Rep; 2003; 10(1):145-50. PubMed ID: 12469161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].
    Yamamoto Y; Kawazoe T; Iwase H
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1415-9. PubMed ID: 16227740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study.
    Vorobiof DA; Rapoport BL; Chasen MR; Slabber C; McMichael G; Eek R; Mohammed C
    Breast; 2004 Jun; 13(3):219-26. PubMed ID: 15177425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
    Naoki K; Kunikane H; Fujii T; Tsujimura S; Hida N; Okamoto H; Watanabe K
    Jpn J Clin Oncol; 2009 Sep; 39(9):569-75. PubMed ID: 19520687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of treatment with high-dose toremifene in patients with metastatic breast cancer resistant to aromatase inhibitor treatment].
    Niikura N; Kimura M; Kobayashi Y; Asahara F; Hayashi K; Shibata S; Shintoku J
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):1013-6. PubMed ID: 19542727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model.
    Dranitsaris G; Rayson D; Vincent M; Chang J; Gelmon K; Sandor D; Reardon G
    Am J Clin Oncol; 2008 Aug; 31(4):369-74. PubMed ID: 18845996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
    Goss P; Bondarenko IN; Manikhas GN; Pendergrass KB; Miller WH; Langecker P; Blanchett D
    J Clin Oncol; 2007 Nov; 25(31):4961-6. PubMed ID: 17971594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Phase I study of NK 622 (toremifene citrate)].
    Tominaga T; Hayashi K; Hayasaka A; Asaishi K; Abe R; Kimishima I; Izuo M; Iino Y; Yokoe T; Abe O
    Gan To Kagaku Ryoho; 1992 Dec; 19(14):2363-72. PubMed ID: 1463343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
    Yamamoto N; Sekine I; Nakagawa K; Takada M; Fukuoka M; Tanigawara Y; Saijo N
    Jpn J Clin Oncol; 2009 Jul; 39(7):425-30. PubMed ID: 19395467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver.
    Camacho LH; Kurzrock R; Cheung A; Barber DF; Gupta S; Madoff DC; Wallace MJ; Kim EE; Curley SA; Hortobagyi GN; Mavligit G
    Cancer; 2007 Jun; 109(11):2190-6. PubMed ID: 17464952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
    Specenier PM; Ciuleanu T; Latz JE; Musib LC; Darstein CL; Vermorken JB
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):233-41. PubMed ID: 19011858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of metastatic breast cancer responding to weekly paclitaxel and high-dose toremifene administrated alternately].
    Murakami H; Noda S; Okamura Y; Sakakibara T; Ishikawa T; Nakamura H; Yaguchi T; Harada A
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):1963-6. PubMed ID: 12465396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene.
    Umemoto A; Lin CX; Ueyama Y; Komaki K; Santosh Laxmi YR; Shibutani S
    Chem Res Toxicol; 2006 Mar; 19(3):421-5. PubMed ID: 16544947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma.
    Gong Y; Ren L; Zhou L; Zhu J; Huang M; Zhou X; Wang J; Lu Y; Hou M; Wei Y
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):327-33. PubMed ID: 19048253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.